Skip to main content
Top
Published in: Neurological Sciences 9/2017

01-09-2017 | Original Article

Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis

Authors: Esteban Simental-Mendía, Luis E. Simental-Mendía, Fernando Guerrero-Romero

Published in: Neurological Sciences | Issue 9/2017

Login to get access

Abstract

It has been reported that patients with multiple sclerosis (MS) exhibit lower serum uric acid levels; however, the association between uric acid concentrations and benign MS (BMS) has not been assessed. Hence, the objective of the present study was to determine whether the serum concentrations of uric acid are associated with the presence of BMS. Men and non-pregnant women over 16 years of age with diagnosis of MS were enrolled in a cross-sectional study. Expanded Disability Status Scale score < 3, progression of disease ≤10 years, diabetes, renal or hepatic diseases, gout, malignancy, alcohol intake, and treatment with thiazide diuretics and/or acetylsalicylic acid were exclusion criteria. According to subtype of disease, the eligible patients were allocated into groups with BMS and other varieties of MS. A logistic regression analysis was conducted in order to evaluate the association between serum concentrations of uric acid and BMS. A total of 106 patients were included, 39 in the group with BMS and 67 in the group with other varieties of MS. The logistic regression analysis adjusted by age, sex, and disease duration showed that increased concentrations of uric acid, indeed within the physiological levels, are significantly associated with the presence of BMS (OR = 2.60; 95% CI: 1.55–4.38, p < 0.001). The results of the present study suggest that elevated concentrations of uric acid, indeed within the physiological range, are likely linked to the presence of BMS.
Literature
1.
2.
3.
go back to reference Traugott U, Reinherz EL, Raine CS (1983) Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 4(3):201–221CrossRefPubMed Traugott U, Reinherz EL, Raine CS (1983) Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 4(3):201–221CrossRefPubMed
4.
go back to reference Raine CS (1994) The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 36(Suppl):S61–S72CrossRefPubMed Raine CS (1994) The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 36(Suppl):S61–S72CrossRefPubMed
5.
go back to reference Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):938–952CrossRefPubMed Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):938–952CrossRefPubMed
6.
go back to reference Liu B, Shen Y, Xiao K, Tang Y, Cen L, Wei J (2012) Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 34(2):163–171PubMed Liu B, Shen Y, Xiao K, Tang Y, Cen L, Wei J (2012) Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 34(2):163–171PubMed
7.
go back to reference Wang L, Hu W, Wang J, Qian W, Xiao H (2016) Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: an updated meta-analysis. Mult Scler Relat Disord 9:17–22CrossRefPubMed Wang L, Hu W, Wang J, Qian W, Xiao H (2016) Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: an updated meta-analysis. Mult Scler Relat Disord 9:17–22CrossRefPubMed
8.
go back to reference Guerrero AL, Gutiérrez F, Iglesias F, Martín-Polo J, Merino S, Martín-Serradilla JI, Laherrán E, Tejero MA (2011) Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 32(2):347–350CrossRefPubMed Guerrero AL, Gutiérrez F, Iglesias F, Martín-Polo J, Merino S, Martín-Serradilla JI, Laherrán E, Tejero MA (2011) Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 32(2):347–350CrossRefPubMed
9.
go back to reference Maesaka JK, Wolf-Klein G, Piccione JM, Ma CM (1993) Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer’s disease. J Am Geriatr Soc 41(5):501–506CrossRefPubMed Maesaka JK, Wolf-Klein G, Piccione JM, Ma CM (1993) Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer’s disease. J Am Geriatr Soc 41(5):501–506CrossRefPubMed
10.
go back to reference Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9(3):221–226CrossRefPubMed Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9(3):221–226CrossRefPubMed
11.
go back to reference Kalnovičová T, Turčáni P (2009) Plasma uric acid levels in multiple sclerosis patients as a marker of disease activity and blood–brain barrier dysfunction. Psychiatrie 13:80–81 Kalnovičová T, Turčáni P (2009) Plasma uric acid levels in multiple sclerosis patients as a marker of disease activity and blood–brain barrier dysfunction. Psychiatrie 13:80–81
12.
go back to reference Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentral Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentral
13.
go back to reference Sayao AL, Devonshire V, Tremlett H (2007) Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 68(7):496–500CrossRefPubMed Sayao AL, Devonshire V, Tremlett H (2007) Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 68(7):496–500CrossRefPubMed
14.
go back to reference Katz Sand I (2015) Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol 28(3):193–205CrossRefPubMed Katz Sand I (2015) Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol 28(3):193–205CrossRefPubMed
15.
go back to reference Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, Arru G, Rosati G (2002) Serum uric acid and multiple sclerosis. Neurol Sci 23(4):183–188CrossRefPubMed Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, Arru G, Rosati G (2002) Serum uric acid and multiple sclerosis. Neurol Sci 23(4):183–188CrossRefPubMed
16.
go back to reference Fang P, Li X, Luo JJ, Wang H, Yang XF (2013) A double-edged sword: uric acid and neurological disorders. Brain Disord Ther 2(2):109PubMedPubMedCentral Fang P, Li X, Luo JJ, Wang H, Yang XF (2013) A double-edged sword: uric acid and neurological disorders. Brain Disord Ther 2(2):109PubMedPubMedCentral
17.
go back to reference Drulović J, Dujmović I, Stojsavljević N, Mesaros S, Andjelković S, Miljković D, Perić V, Dragutinović G, Marinković J, Lević Z, Mostarica Stojković M (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248(2):121–126CrossRefPubMed Drulović J, Dujmović I, Stojsavljević N, Mesaros S, Andjelković S, Miljković D, Perić V, Dragutinović G, Marinković J, Lević Z, Mostarica Stojković M (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248(2):121–126CrossRefPubMed
18.
go back to reference van der Veen RC, Hinton DR, Incardonna F, Hofman FM (1997) Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J Neuroimmunol 77(1):1–7CrossRefPubMed van der Veen RC, Hinton DR, Incardonna F, Hofman FM (1997) Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J Neuroimmunol 77(1):1–7CrossRefPubMed
19.
go back to reference Ramsaransing GS, Heersema DJ, De Keyser J (2005) Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. Eur J Neurol 12(7):514–518CrossRefPubMed Ramsaransing GS, Heersema DJ, De Keyser J (2005) Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. Eur J Neurol 12(7):514–518CrossRefPubMed
20.
go back to reference Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda H, Koprowski H (1997) Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 94(6):2528–2533CrossRefPubMedPubMedCentral Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda H, Koprowski H (1997) Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 94(6):2528–2533CrossRefPubMedPubMedCentral
21.
go back to reference Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 95(2):675–680CrossRefPubMedPubMedCentral Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 95(2):675–680CrossRefPubMedPubMedCentral
22.
go back to reference Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowskil H (2001) Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 7(5):313–319CrossRefPubMed Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowskil H (2001) Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 7(5):313–319CrossRefPubMed
23.
go back to reference Constantinescu CS, Freitag P, Kappos L (2000) Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 6(6):378–381CrossRefPubMed Constantinescu CS, Freitag P, Kappos L (2000) Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 6(6):378–381CrossRefPubMed
Metadata
Title
Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis
Authors
Esteban Simental-Mendía
Luis E. Simental-Mendía
Fernando Guerrero-Romero
Publication date
01-09-2017
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 9/2017
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-017-3043-1

Other articles of this Issue 9/2017

Neurological Sciences 9/2017 Go to the issue